Title : Company blamed for fueling fentanyl addiction crisis will soon sell synthetic cannabis
link : Company blamed for fueling fentanyl addiction crisis will soon sell synthetic cannabis
Company blamed for fueling fentanyl addiction crisis will soon sell synthetic cannabis
- Insys Therapeutics has developed a synthetic formula for THC, the main psychoactive component in marijuana
- The DEA is close to approving the drug called Syndros
- The oral spray has been approved by the FDA to treat nausea, vomiting and weight loss in AIDS and cancer patients
- Last fall Insys was accused of pushing prescriptions for fentanyl, an opioid that is 50 times stronger than heroin
- Medical-grade synthetic marijuana is not to be confused with street versions that are an unpredictable mix of chemicals causing eye bleeding in Illinois
The drug manufacturer accused of fueling the opioid epidemic will soon be given the green light to market synthetic marijuana for medical use.
The US Drug Enforcement Agency is close to approving a synthetic formula for THC, the main psychoactive component in marijuana, made by Insys Therapeutics.
The company has said launching the new drug Syndros will be a 'pivotal milestone' to turn around Insys's reputation following several lawsuits alleging its top execs have been pushing prescriptions for fentanyl, an opioid that is 50 times stronger than heroin.
The new drug could potentially replace highly addictive and dangerous drugs like fentanyl that are fueling the opioid epidemic that kills thousands of Americans each year.
Pharmaceutical company Insys Therapeutics will soon be approved to market a synthetic marijuana product called Syndros for medical use
Medical-grade synthetic marijuana is not to be confused with street versions known as 'K2' or 'spice' that are an unpredictable mix of chemicals recently found to cause severe bleeding from the eyes and ears in Illinois.
Medical synthetics are scientifically and specifically calibrated to mimic cannabinoids, the active compounds in marijuana that create the 'high'.
They are similar to chemicals the body makes that are involved in appetite, memory, movement, and pain.
The two main cannabinoids are THC and CBD.
Syndros is a synthetic formula for THC. The main component of the drug, dronabinol, was first government-approved in pill-capsule form in 1985. It is sold under the name Marinol.
Once it receives final DEA approval, Insys will be able to start selling oral spray intended to treat nausea, vomiting and weight loss in AIDS and cancer patients by mimicking THC.
In November the DEA announced that Syndros will be classified as a Schedule II controlled substance, meaning it can be legally prescribed by doctors.
Schedule II drugs including cocaine, fentanyl and morphine are considered to have a 'high potential for abuse'.
Natural marijuana is currently listed in the more restrictive Schedule I category, which is reserved for drugs that have 'no currently accepted medical use'.
The Schedule II classification indicates that the DEA considers the synthetic marijuana to be safer and more valuable that regular marijuana.
Last fall Insys founder John Kapoor and several other top executives at the company were accused of offering bribes to doctors to write large numbers of prescriptions for the fentanyl-based spray called Subsys.
Subsys was only approved by the FDA for used by cancer patients with severe nerve pain, but an investigation found that most of the people who received prescriptions did not have cancer.
Although originally intended as a painkiller with medicinal uses, the substance has increasingly been used an illicit recreational drug and is often made illegally.
More than 20,000 deaths occurred in the United States in 2016 from fentanyl overdoses alone.
Thus Article Company blamed for fueling fentanyl addiction crisis will soon sell synthetic cannabis
You are now reading the article Company blamed for fueling fentanyl addiction crisis will soon sell synthetic cannabis with the link address https://coneknews.blogspot.com/2018/04/company-blamed-for-fueling-fentanyl.html
0 Response to "Company blamed for fueling fentanyl addiction crisis will soon sell synthetic cannabis"
Post a Comment